No Data
No Data
Jinshi Asia Pharmaceutical (300434.SZ): AI technology has not been applied in drug research and development
Gelonghui, April 30 | Jinshi Yayao (300434.SZ) said on the investor interactive platform that currently the application of AI technology in drug development mainly focuses on drug design and optimization, prediction of adverse reactions and clinical trials, and patient recruitment. The company has not yet applied AI technology to drug research and development. The company is actively promoting drug research and development through multiple channels such as independent research and development, outsourced R&D, and document acquisition. Please pay attention to the company's announcements regarding the company's drug development.
Jinshi Pharmaceutical (300434.SZ) announced first-quarter results, net profit of 898.16,200 yuan, a year-on-year decrease of 37.39%
Jinshi Pharmaceutical (300434.SZ) released its report for the first quarter of 2024. The company achieved operating revenue during the period...
Express News | Jinshi Asia Pharmaceutical: The company currently has no oseltamivir related products on the market
Jinshi Asia Pharmaceutical (300434.SZ): Plans to jointly invest in Lingye Pharmaceutical with related parties
Gelonghui, December 28 | Jinshi Ya Pharmaceutical (300434.SZ) announced that the company recently signed a “Capital Increase Agreement on Hangzhou Lingye Pharmaceutical Technology Development Co., Ltd.” (“Dragon Fruit Investment”), Hangzhou Dragon Fruit Investment Management Co., Ltd. (“Dragon Fruit Investment”), and natural person Ms. Gao Yaping. The company and Ms. Gao Yaping and Dragon Fruit Investment plan to invest a total of RMB 694.885,700 to subscribe to Lingye Pharmaceutical with an additional registered capital of RMB 27.72,89.4 million. Among them, the company plans to use RMB 3154.0
Jinshi Yayao (300434.SZ): In terms of childhood pneumonia, the main production and marketing varieties include azithromycin dry suspension, ambroxol hydrochloride oral solution, etc.
Gelonghui, December 12|Jinshi Yayao (300434.SZ) said on the investor interactive platform that in terms of colds and fevers in children, our company mainly produces and sells pediatric aminophen granules, ibuprofen granules, cold and fever-clearing granules, pentane root granules, antiviral oral solution, etc.; in terms of childhood pneumonia, the main products and marketing varieties include azithromycin dry suspensions, amoxicillin granules, cefixime granules, ambroxol hydrochloride oral solution, etc.; it can provide different symptoms for children Medications provide symptomatic treatment.
Jinshi Yayao (300434.SZ): Net profit increased 89.45% to 156 million yuan in the first half of the year
Gelonghui, August 28: Jinshi Yayao (300434.SZ) announced its 2023 semi-annual report. Operating revenue for the reporting period was 634 million yuan, up 32.18% year on year; net profit attributable to shareholders of listed companies was 156 million yuan, up 89.45% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 1,496 billion yuan, up 137.42% year on year; basic earnings per share were 0.3876 yuan.
No Data